CD8A and myeloid sarcoma: An early increase in the circulating CD8+CD28−CD57+ cells has been seen across studies of AHSCT in MS (129, 133, 135), and it has been suggested that this population is a significant contributor to the rise seen in the aforementioned CD8+ TM population in the initial months post-AHSCT (133).